Following a European Parliamentary vote last summer in favor of a final Regulation for Pediatric Medicines, this legislation was adopted at the end of last year and comes into force on January 26 (Marketletters passim). The Regulation aims to establish a legislative framework that will fulfil the following main objectives:
- increased availability of medicines specifically adapted and licensed for use in the pediatric population;
- increased information available to the patient/carer and prescriber about the use of medicines in children, including clinical trial data; and
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze